Abstract |
An intense effort has been launched to develop improved anthrax vaccines that confer rapid, long lasting protection preferably with an extended stability profile amenable for stockpiling. Protective antigen (PA)-based vaccines are most favored as immune responses directed against PA are singularly protective, although the actual protective mechanism remains to be unraveled. Herein we show that contrary to the prevailing view, an efficacious PA-based vaccine confers protection against inhalation anthrax by preventing the establishment of a toxin-releasing systemic infection. Equally importantly, antibodies measured by the in vitro lethal toxin neutralization activity assay (TNA) that is considered as a reliable correlate of protection, especially for PA protein-based vaccines adjuvanted with aluminum salts appear to be not absolutely essential for this protective immune response.
|
Authors | Tod J Merkel, Pin-Yu Perera, Gloria M Lee, Anita Verma, Toyoko Hiroi, Hiroyuki Yokote, Thomas A Waldmann, Liyanage P Perera |
Journal | Human vaccines & immunotherapeutics
(Hum Vaccin Immunother)
Vol. 9
Issue 9
Pg. 1841-8
(Sep 2013)
ISSN: 2164-554X [Electronic] United States |
PMID | 23787486
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anthrax Vaccines
- Antibodies, Bacterial
- Antibodies, Neutralizing
- Antigens, Bacterial
- Bacterial Toxins
- anthrax toxin
|
Topics |
- Animals
- Anthrax
(immunology, prevention & control)
- Anthrax Vaccines
(immunology)
- Antibodies, Bacterial
(blood)
- Antibodies, Neutralizing
(blood)
- Antigens, Bacterial
(immunology)
- Bacterial Toxins
(immunology)
- Female
- Humans
- Rabbits
- Respiratory Tract Infections
(immunology, prevention & control)
|